Evolent Health, Inc. (NYSE:EVH) Receives $21.92 Average PT from Analysts

Shares of Evolent Health, Inc. (NYSE:EVH - Get Free Report) have been assigned a consensus recommendation of "Buy" from the thirteen research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $21.92.

A number of analysts recently issued reports on EVH shares. JPMorgan Chase & Co. decreased their target price on Evolent Health from $45.00 to $15.00 and set an "overweight" rating for the company in a research report on Friday, November 22nd. Stephens cut shares of Evolent Health from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $38.00 to $16.00 in a report on Friday, November 8th. Needham & Company LLC began coverage on shares of Evolent Health in a research note on Friday, January 10th. They set a "buy" rating and a $15.00 price target for the company. JMP Securities lowered their price objective on shares of Evolent Health from $27.00 to $18.00 and set a "market outperform" rating on the stock in a research report on Friday, January 10th. Finally, BTIG Research reduced their target price on shares of Evolent Health from $36.00 to $29.00 and set a "buy" rating for the company in a report on Tuesday, December 3rd.

Institutional Investors Weigh In On Evolent Health

Several institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new stake in shares of Evolent Health during the 2nd quarter worth approximately $32,000. Covestor Ltd boosted its position in Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC grew its holdings in Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock valued at $45,000 after purchasing an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Evolent Health in the second quarter valued at $61,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Evolent Health during the 2nd quarter worth $148,000.

Evolent Health Stock Down 1.4 %

NYSE:EVH traded down $0.14 during midday trading on Monday, hitting $10.02. 2,709,253 shares of the company were exchanged, compared to its average volume of 1,566,778. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a fifty-two week low of $9.88 and a fifty-two week high of $35.00. The company has a market capitalization of $1.17 billion, a PE ratio of -11.01 and a beta of 1.45. The company has a fifty day simple moving average of $11.79 and a 200 day simple moving average of $20.73.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.